skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Selatinib Ditosilate (Code C111764)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Selatinib Ditosilate

Definition: An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.

Label: Selatinib Ditosilate

NCI Thesaurus Code: C111764 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL454151  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Selatinib Ditosilate

External Source Codes: 
PDQ Closed Trial Search ID 753197
PDQ Open Trial Search ID 753197 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C111764
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom